- Actively dividing tumors appear to progress to a life-threatening condition more rapidly than slowly dividing tumors.
- The assessment of actively dividing tumors currently involves a manual enumeration of mitotic cells in a histological slide prepared from the tumor and assessed by a trained pathologist.
- Moffitt researchers have invented a method of using gene expression data to identify patients with slightly more aggressive forms of tumors that might require closer monitoring or chemotherapeutic intervention.
FEATURES AND BENEFITS
- The basic principle is that the gene expression data from a group of selected genes is assessed to identify adenocarcinoma tumor samples with a high rate of mitosis and thus a higher likelihood of having a poor response to treatment.
- The genes involved are those in the regulation of the cell cycle and the mitotic process, to assess the overall mitotic state of a tumor sample.
- Gene expression levels can be assessed with data from microarrays or Q-PCR.
- The genes and the mechanism for evaluating them are possibly applicable to a variety of tumor types in addition to adenocarcinoma.
STAGE OF DEVELOPMENT
Planned prospective validation.
- Director’s Challenge Consortium et al. (2008) Nature Medicine 14:822-827.
- US patent application filed.
Haskell Adler PhD MBA CLP
Senior Licensing Manager
Registered Patent Agent